Literature DB >> 20005278

Pediatric neurological syndromes and inborn errors of purine metabolism.

Marcella Camici1, Vanna Micheli, Piero Luigi Ipata, Maria Grazia Tozzi.   

Abstract

This review is devised to gather the presently known inborn errors of purine metabolism that manifest neurological pediatric syndromes. The aim is to draw a comprehensive picture of these rare diseases, characterized by unexpected and often devastating neurological symptoms. Although investigated for many years, most purine metabolism disorders associated to psychomotor dysfunctions still hide the molecular link between the metabolic derangement and the neurological manifestations. This basically indicates that many of the actual functions of nucleosides and nucleotides in the development and function of several organs, in particular central nervous system, are still unknown. Both superactivity and deficiency of phosphoribosylpyrophosphate synthetase cause hereditary disorders characterized, in most cases, by neurological impairments. The deficiency of adenylosuccinate lyase and 5-amino-4-imidazolecarboxamide ribotide transformylase/IMP cyclohydrolase, both belonging to the de novo purine synthesis pathway, is also associated to severe neurological manifestations. Among catabolic enzymes, hyperactivity of ectosolic 5'-nucleotidase, as well as deficiency of purine nucleoside phosphorylase and adenosine deaminase also lead to syndromes affecting the central nervous system. The most severe pathologies are associated to the deficiency of the salvage pathway enzymes hypoxanthine-guanine phosphoribosyltransferase and deoxyguanosine kinase: the former due to an unexplained adverse effect exerted on the development and/or differentiation of dopaminergic neurons, the latter due to a clear impairment of mitochondrial functions. The assessment of hypo- or hyperuricemic conditions is suggestive of purine enzyme dysfunctions, but most disorders of purine metabolism may escape the clinical investigation because they are not associated to these metabolic derangements. This review may represent a starting point stimulating both scientists and physicians involved in the study of neurological dysfunctions caused by inborn errors of purine metabolism with the aim to find novel therapeutical approaches. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005278     DOI: 10.1016/j.neuint.2009.12.003

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  18 in total

1.  Metabolic disorders of purine metabolism affecting the nervous system.

Authors:  H A Jinnah; Richard L Sabina; Georges Van Den Berghe
Journal:  Handb Clin Neurol       Date:  2013

2.  Purine metabolism during neuronal differentiation: the relevance of purine synthesis and recycling.

Authors:  Martin Göttle; Heike Burhenne; Diane Sutcliffe; H A Jinnah
Journal:  J Neurochem       Date:  2013-08-18       Impact factor: 5.372

3.  Mycophenolate mofetil for sustained remission in nephrotic syndrome.

Authors:  Uwe Querfeld; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2018-05-11       Impact factor: 3.714

4.  Neurological basis of AMP-dependent thermoregulation and its relevance to central and peripheral hyperthermia.

Authors:  Mirko Muzzi; Francesco Blasi; Alessio Masi; Elisabetta Coppi; Chiara Traini; Roberta Felici; Maria Pittelli; Leonardo Cavone; Anna Maria Pugliese; Flavio Moroni; Alberto Chiarugi
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-24       Impact factor: 6.200

5.  Consequences of impaired purine recycling on the proteome in a cellular model of Lesch-Nyhan disease.

Authors:  Eric B Dammer; Martin Göttle; Duc M Duong; John Hanfelt; Nicholas T Seyfried; H A Jinnah
Journal:  Mol Genet Metab       Date:  2015-03-05       Impact factor: 4.797

Review 6.  Regulation of adenosine levels during cerebral ischemia.

Authors:  Stephanie Chu; Wei Xiong; Dali Zhang; Hanifi Soylu; Chao Sun; Benedict C Albensi; Fiona E Parkinson
Journal:  Acta Pharmacol Sin       Date:  2012-10-15       Impact factor: 6.150

7.  Prenatal growth restriction, retinal dystrophy, diabetes insipidus and white matter disease: expanding the spectrum of PRPS1-related disorders.

Authors:  Almundher Al-Maawali; Lucie Dupuis; Susan Blaser; Elise Heon; Mark Tarnopolsky; Fathiya Al-Murshedi; Christian R Marshall; Tara Paton; Stephen W Scherer; Jeroen Roelofsen; André B P van Kuilenburg; Roberto Mendoza-Londono
Journal:  Eur J Hum Genet       Date:  2014-06-25       Impact factor: 4.246

Review 8.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

9.  AMPD2 regulates GTP synthesis and is mutated in a potentially treatable neurodegenerative brainstem disorder.

Authors:  Naiara Akizu; Vincent Cantagrel; Jana Schroth; Na Cai; Keith Vaux; Douglas McCloskey; Robert K Naviaux; Jeremy Van Vleet; Ali G Fenstermaker; Jennifer L Silhavy; Judith S Scheliga; Keiko Toyama; Hiroko Morisaki; Fatma M Sonmez; Figen Celep; Azza Oraby; Maha S Zaki; Raidah Al-Baradie; Eissa A Faqeih; Mohammed A M Saleh; Emily Spencer; Rasim Ozgur Rosti; Eric Scott; Elizabeth Nickerson; Stacey Gabriel; Takayuki Morisaki; Edward W Holmes; Joseph G Gleeson
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

10.  Inborn errors of purine metabolism: clinical update and therapies.

Authors:  Shanti Balasubramaniam; John A Duley; John Christodoulou
Journal:  J Inherit Metab Dis       Date:  2014-06-28       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.